Insights into the gut microbiome of vitiligo patients from IndiaOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined the gut microbiome in vitiligo, an autoimmune skin depigmentation disorder, to explore a possible gut-skin axis. It compared taxonomic composition, predicted function, and community structure between patients and healthy controls. Fecal microbiomes were profiled by 16S rRNA amplicon sequencing of the V3 region. Predicted functions were inferred with PICRUSt2. Co-occurrence networks and a random forest classifier trained across two cohorts were used to find robust microbial markers.
Who was studied?
The cohort was 32 adults from India: 22 with vitiligo and 10 age and gender matched healthy controls. The vitiligo group included 12 patients with no family history and 10 with a first-degree relative affected. Participants were recruited over two years at AIIMS Bhopal. Those on antibiotics or steroids were excluded. Blood measures included T-cell subsets and serum IL-10. For a cross-population analysis, the team added a published French cohort of 10 vitiligo patients and 10 controls.
What were the most important findings?
Patients and controls clustered separately, with significant beta-diversity differences (p equals 0.005, Bray-Curtis). Alpha diversity was only slightly lower in patients and not significant. The vitiligo group had a significantly lower Firmicutes to Bacteroidetes ratio (p equals 0.005). Butyrate-producing Lachnospiraceae members and other healthy commensals were depleted. Predicted functions showed more mucin-degrading genes, suggesting a weakened mucus barrier, plus higher fatty acid and lipid metabolism genes. Serum IL-10 was lower in patients. A cross-cohort classifier separated patients from controls with about 82 percent accuracy, with short chain fatty acid producers among the top genera.
What are the greatest implications of this study?
The results strengthen evidence that gut dysbiosis accompanies vitiligo and may contribute to disease through immune modulation and a compromised gut barrier. Reduced short-chain fatty acid producers could weaken regulatory T-cell support. This is the first vitiligo gut microbiome data from a non-Western Indian cohort, and shared markers across populations suggest common mechanisms across autoimmune conditions. The study is cross-sectional and small, so it cannot prove causation. The authors suggest diet and probiotic interventions merit future exploration.